Wikipedia -WSS

Wikipedia

author：explore 2025-09-29 01:38:54 - browse：15

Treeline Northwest — AP Photo/Ted S. Warren

Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No surprise, then, that his next effort has already raised at least $473 million in funding from private investors even before telling the public what, exactly, it is working on.

Treeline Biosciences, the new venture by Bilenker and Jeffrey Engelman, formerly Novartis’s top cancer researcher, has hired more than 130 people across three research sites in little more than a year, according to a company blog post, regulatory filings, and STAT reporting.

Treeline’s website doesn’t mention a single drug target or disease. In a paper published last year in Nature Cancer, Engelman and several colleagues reviewed the history of a class of cancer drugs called PI3 kinase inhibitors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： First Opinion on colorectal cancer screening: letter and response

WSS

Four alarming medical procedures we’re glad history forgot

Mass General Brigham physicians react to latest merger step

Republican states more likely to report Covid vaccine side effects

Researchers tackle phage therapy hurdles for wider adoption

Bird flu in dairy cattle: New measures to control spread to humans

Reporting on presidential health from Reagan to Trump and Biden

knowledge

Wikipedia

focus

Supreme Court strikes down use of affirmative action

A new drug could help frostbite victims avoid its ravages

Walensky prepares to leave CDC — and Congress — behind

Flagship Pioneering startup Sonata Therapeutics lays off 21

In age of alternative facts, a scholarly course on calling out crap

Covid silver lining: Unprecedented look at human immune system

Hollywood unions extend contract negotiations for actors

Weight loss drugs aren’t covered by Obamacare. That may change

Moonlake's readout produced a cash windfall. Risks remain

Flagship Pioneering startup Sonata Therapeutics lays off 21

leisure time

Hospitals are piloting generative AI tools as regulators play catch

Insurer loopholes limit power of law against surprise medical bills

Surprise medical billing ban raises prices elsewhere

Covid silver lining: Unprecedented look at human immune system

New CMS data security rules will hurt Medicare, Medicaid research

Obamacare plans could cover weight loss drugs

hotspot

Wikipedia

entertainment

leisure time